• Zealand Pharma sold its economic interests tied to rusfertide to Royalty Pharma for USD 100 million in a royalty purchase agreement.
• Deal includes a 1% royalty on potential future global net sales, regulatory milestones, commercial milestones.
• USD 50 million payable at closing; remaining USD 50 million due on the first anniversary of closing.
• Zealand retains a 0.25% royalty on annual net global sales above USD 1.5 billion; Royalty Pharma holds 0.75% above that level.
• Transaction closed today; FDA PDUFA goal date for rusfertide set for Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zealand Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608121605OMX_____CNEWS_EN_GNW1001257327_en) on August 12, 2026, and is solely responsible for the information contained therein.